OMN6 – Omnix Medical’s Lead Antimicrobial Peptide Receives Notice of Allowance from the Indian Patent Office

We are here to announce that the Indian Patent Office has issued a Notice of Allowance for Omnix Medical’s lead antimicrobial peptide for the treatment of infectious diseases. This pivotal achievement signifies that OMN6, developed with a commitment to revolutionize infectious disease treatment, has met the stringent criteria required for intellectual property protection.

Importantly, the Notice of Allowance follows the patent protection previously granted to OMN6 in several other major international markets, including the United States, European Union, China, Australia, and Japan. The repeated validation from patent offices worldwide testifies to the unique, innovative, and significant nature of our work in fighting infectious diseases.

Our dedicated team of scientists has invested countless hours in the development of this peptide, with the goal of delivering a novel, effective, and accessible solution for AMR and for the treatment of infectious diseases globally.

With this Notice of Allowance, the intellectual property for our lead peptide is officially recognized and protected until 2037. This provides our company with the exclusive rights to further develop and commercialize our pioneering antimicrobial peptide. It also ensures that we can continue our vital work to advance this treatment without the fear of any patent infringement.

As we move forward, we remain committed to pushing the boundaries of biotechnology to improve healthcare outcomes worldwide. We will keep you updated as we embark on the next clinical phase of our journey.

Thank you for your continued support and trust in our mission.